[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100243300":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":27,"responsibleParty":42,"collaborators":7,"id":45,"slug":7,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":29,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"University Medical Centre Ljubljana","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","Autologous stem cell therapy","All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg\u002Fkg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.",[14],{"name":15,"affiliation":16,"role":17},"Bojan Vrtovec, MD, PhD","UMC Ljubljana","PRINCIPAL_INVESTIGATOR",[19,23],{"name":15,"role":20,"phone":21,"phoneExt":7,"email":22},"CONTACT","+3861 522 1157","bojan.vrtovec@gmail.com",{"name":24,"role":20,"phone":25,"phoneExt":7,"email":26},"Gregor Poglajen, MD, PhD","+3861 522 1148","gregor.poglajen@gmail.com",[28],{"facility":16,"status":29,"city":30,"state":7,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Ljubljana","1000","Slovenia",{"type":34,"coordinates":35},"Point",[36,37],14.50513,46.05108,{"lat":37,"lon":36},[40,41],{"name":15,"role":20,"phone":21,"phoneExt":7,"email":22},{"name":24,"role":20,"phone":25,"phoneExt":7,"email":26},{"type":17,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Bojan Vrtovec","Medical Director, Advanced Heart Failure and Transplantation Center","100243300",false,"NCT02445534","Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy","RECORD","Inclusion Criteria:\n\n* Patient inclusion criteria consisted of the following: age 18-65 years old, diagnosis of DCM according to the European Society of Cardiology position statement (9), optimal medical management for at least 6 months, left ventricular ejection fraction (LVEF) \\\u003C40%, and New York Heart Association functional Class III on stable medical therapy for at least 3 months before referral.\n\nExclusion Criteria:\n\n* Patients with acute multi-organ failure or a history of hematologic neoplasms were not included.","ALL","18 Years","65 Years",{"count":55,"type":56},250,"ESTIMATED","5 Years","OBSERVATIONAL","Although several studies have demonstrated beneficial effects of stem cell therapy in patients with non-ischemic dilated cardiomyopathy, the long term benefits and predictors of response to therapy remain undefined. The aim of this registry is to pool long-term clinical data in patients with non-ischemic dilated cardiomyopathy undergoing autologous cell therapy in an attempt to better define predictors of response to such treatment.",[61],"Cardiomyopathy, Dilated",[63],"Cell Therapy","2024-07-01",{"date":66,"type":67},"2024-07-03","ACTUAL",{"date":69,"type":7},"2005-01",{"date":71,"type":56},"2027-05",{"name":5,"class":6},1]